BOTOX瘦面針優惠價錢｜打BOTOX去皺效果｜MIOGGI

 

主頁 > 醫學美容 > 輪廓塑形 >

BOTOX® 瘦面緊緻去皺

BOTOX®保妥適的英文全名是 Botulinum Toxin Type A，它是一種由桿菌素提煉而成的天然純化蛋白質，可作神經傳導阻斷劑使用。BOTOX®具有放鬆肌肉的功效，MIOGGI採用定點定量注術，可令過度活躍的肌肉得以放鬆，從而改善眉間、額頭、眼尾、鼻翼、唇周紋等動態皺紋。除此之外，BOTOX® 亦可達到瘦面、瘦小腿、瘦斜方肌等功效，更有效改善腋下、手掌或腳掌多汗症問題，視乎部位，療效可維持約6-12個月¹

甚麼是
BOTOX® 瘦面緊緻去皺療程？
BOTOX 主要成分為肉毒桿菌素A型(Botulinum Toxin Type A)，是一種高度純化的蛋白質，主要用於瘦面、淡紋、瘦小腿、止汗、提升面部輪廓及放鬆斜方肌。

BOTOX® 肉毒桿菌素是如何運作？
透過注射BOTOX 肉毒桿菌素，阻隔神經末梢訊息傳遞，有效放鬆並撫平動態紋、自然瘦面等顯著效果。

為甚麼選擇BOTOX® 肉毒桿菌素？

BOTOX® 肉毒桿菌素特點

真實個案

官方認證 原廠正貨

BOTOX肉毒桿菌療程效果能維持多久？

BOTOX肉毒桿菌療程能維持達6個月18，客人可根據自己的情況或需要而接受下一次療程。

我想接受BOTOX肉毒桿菌療程，但我聽說它是由毒素製成的，它是否安全？

BOTOX肉毒桿菌療程是一種在嚴格監控下製造而成的高度純化蛋白質#，其全球臨床經驗長達30年，並獲美國FDA認證^，安全性在國際受到充分評估。

若長期使用BOTOX肉毒桿菌療程，劑量會一次比一次提高嗎？

不會，專業醫生每次會依療程部位與肌肉收縮強度而決定所需劑量，臨床研究顯示，BOTOX肉毒桿菌療程會隨著療程次數的增加而延長效果的持續期，所以持續使用可逐漸減少療程的次數17。

會造成臉部肌肉僵硬？臉部肌肉會否受損嗎？

BOTOX肉毒桿菌療程只針對療程部位產生作用，針對性放鬆過於活躍的面部肌肉以達至去皺效果#，正確使用下並不會引起面部僵硬及構成傷害。

BOTOX肉毒桿菌療程可與透明質酸一起使用嗎？

可以。同時使用可以達致更理想的效果。舉例來說，若眉心紋形成已久並出現靜態紋，建議先接受BOTOX肉毒桿菌療程使肌肉放鬆#，再接受透明質酸療程來修飾靜態紋，恢復平滑肌膚。

‡: Medical Insight, Inc 2022. Cosmetic Neurotoxin Market Study. January 2022. Based on worldwide neurotoxins 2021 (in sales value). #: BOTOX® Prescribing Information. HK-41906. May 2013. : Allergan Aesthetics. Data on File. REF-119535. Total number of BOTOX vials shipped as of 5 December 2022.^: U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter SUPPL-5303, October 2, 2017.References: 1. Trindade de Almeida A et al. Dermatol Surg 2015; 41: S19-S28. 2. Yu W et al. J Cosmet Laser Ther. 2018Oct;20(5):278-286. 3. U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter 85-0226 & 85-0227, December 29, 1989. 4. Allergan. Unpublished Data. INT-BCT-2050129 – Worldwide BOTOX® marketing authorization status. October 2020. 5. Allergan. Unpublished Data. REF-100250. BOTOX® number of peer-reviewed articles vs competitors. August 2022. 6. Michaud T, et al. J Cosmet Dermatol. 2015;14(1):9–21. 7. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Decker, Inc; 1994: 15-39. 8. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:3-13. 9. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:41-49. 10. Simpson LL. The actions of clostridial toxins on storage and release of neurotransmitters. In: Harvey AL, ed. Natural and Synthetic Neurotoxins (Neuroscience Perspectives). San Diego, CA: Academic Press; 1993:278-317. 11. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103(2):535-544. 12. Lebeda FJ, Hack DC, Bentry MK. Theoretical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallet M, ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:51-61. 13. Harvey AL. Presynaptic toxins. In: Smythies JR, Bradley RJ, ed. International Review of. 14. Neurobiology. San Diego, CA: Academic Press; 1990:201-239. 15. Tremaine AM, McCullough JL. Clin Cosmet Investig Dermatol. 2010;3:15–23. 16. Stotland MA et al. Plast Reconstr Surg 2007; 120(5):1386-9. 17. Beer KR et al. J Drugs Dermatol 2011;10:39-41. 18. De Boulle K et al. Dermatol Surg. 2018;44[11]:1437-1448. 19. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e. 20. Juvéderm® (Hyaluronic Acid Gel with Lidocaine) product series includes VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA® (HKMD-210451) and VOLITE™ (HKMD-180040).